Unlock stock picks and a broker-level newsfeed that powers Wall Street.

XETRA - Delayed Quote EUR

Becton, Dickinson and Company (BOX.DE)

Compare
176.50
-3.40
(-1.89%)
At close: April 17 at 5:35:31 PM GMT+2

Key Executives

Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.
NameTitlePayExercisedYear Born
Mr. Thomas E. Polen Jr. President, CEO & Chairman 3.28M -- 1973
Mr. Christopher J. DelOrefice CPA Executive VP & CFO 1.56M -- 1972
Ms. Shana Carol Neal Executive VP & Chief People Officer 1.22M -- 1966
Mr. Michael Garrison Executive VP & President of Medical segment 1.17M -- 1970
Mr. Richard Byrd Executive VP & President of Interventional Segment 1.21M -- 1968
Ms. Pamela L. Spikner Senior VP, Chief Accounting Officer & Controller -- -- 1978
Ms. Elizabeth McCombs Executive VP & Chief Technology Officer -- -- 1977
Dr. Joseph M. Smith F.A.C.C, M.D., Ph.D. Senior VP & Chief Scientific Officer -- -- --
Ms. Denise Russell Fleming Executive VP of Technology & Global Services and Chief Information Officer -- -- 1971
Mr. Greg Rodetis Senior VP, Treasurer & Head of Investor Relations -- -- --

Becton, Dickinson and Company

1 Becton Drive
Franklin Lakes, NJ 07417-1880
United States
201 847 6800 https://www.bd.com
Sector: 
Healthcare
Full Time Employees: 
70,000

Description

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation systems, and medication inventory optimization and tracking systems; hemodynamic monitoring systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

Corporate Governance

Becton, Dickinson and Company’s ISS Governance QualityScore as of April 1, 2025 is 3. The pillar scores are Audit: 5; Board: 5; Shareholder Rights: 1; Compensation: 7.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

May 1, 2025 at 12:30 PM UTC

Becton, Dickinson and Company Earnings Date

Recent Events

March 10, 2025 at 12:00 AM UTC

Ex-Dividend Date

Related Tickers